Recommendations
This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
Definitions and criteria for the categorisation of medicines
Legacy Merseyside
New Cheshire and Merseyside
Transition of Commissioning Policies
On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.
Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.
Documents
The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of DAPAGLIFLOZIN and EMPAGLIFLOZIN, following specialist recommendation, as options for treating symptomatic chronic heart failure with reduced ejection fraction in accordance with NICE TA679 and NICE TA773, and symptomatic chronic heart failure with preserved or mildly reduced ejection fraction, in accordance with NICE TA902 and TA929.
GP communication letter: SGLT2 inhibitors in heart failure
Pathway for the use of SGLT2 inhibitors in heart failure
NHS Cheshire and Merseyside APPROVED